<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> effectiveness is impaired in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesize that <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> contribute importantly to this defect </plain></SENT>
<SENT sid="2" pm="."><plain>To test this hypothesis, we compared the effect of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> on <z:chebi fb="105" ids="17234">glucose</z:chebi> turnover in type 2 diabetic subjects in good control (GC) (n = 14, age 51.7 +/- 3.7 years, BMI 28.4 +/- 1.0 kg/ m(2), HbA(1c) 5.9 +/- 0.2%) and poor control (PC) (n = 10, age 50.0 +/- 2.5 years, BMI 27.9 +/- 1.5 kg/m(2), HbA(1c) 9.9 +/- 0.6%) with age- and weight-matched nondiabetic subjects (ND) (n = 11, age 47.0 +/- 4.4 years, BMI 28.5 +/- 1.0 kg/m(2), HbA(1c) 5.1 +/- 0.2%) </plain></SENT>
<SENT sid="3" pm="."><plain>Fixed hormonal conditions were attained by infusing somatostatin for 6 h with replacement of basal insulin, glucagon, and growth hormone </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="105" ids="17234">Glucose</z:chebi> fluxes ([3-(3)H]<z:chebi fb="105" ids="17234">glucose</z:chebi>) were compared during euglycemic (5 mmol/l, t = 180-240 min) and hyperglycemic (Hy) (10 mmol/l, t = 300-360 min, variable <z:chebi fb="105" ids="17234">glucose</z:chebi> infusion) clamp intervals </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> suppressed hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production (GP) by 43% and increased peripheral <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake (GU) by 86% in the ND subjects </plain></SENT>
<SENT sid="6" pm="."><plain>Conversely, GP failed to suppress (-7%) and GU was suboptimally increased (+34%) in response to Hy in the PC group </plain></SENT>
<SENT sid="7" pm="."><plain>However, optimal glycemic control was associated with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness in GC subjects (GP -38%, GU +72%; P &gt; 0.05 for GC vs. ND) </plain></SENT>
<SENT sid="8" pm="."><plain>To determine whether short-term correction of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and/or <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> is sufficient to reverse the impairment in <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness, five PC subjects were restudied after 72 h of normoglycemia ( approximately 100 mg/dl; variable insulin infusions) </plain></SENT>
<SENT sid="9" pm="."><plain>These subjects regained <z:mpath ids='MPATH_458'>normal</z:mpath> effectiveness of <z:chebi fb="105" ids="17234">glucose</z:chebi> to suppress GP and stimulate GU and in response to Hy (GP -47%, GU + 71%; P &gt; 0.05 vs. baseline studies) </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and/or <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> contribute to impaired effectiveness of <z:chebi fb="105" ids="17234">glucose</z:chebi> in regulating <z:chebi fb="105" ids="17234">glucose</z:chebi> fluxes in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and hence to worsening of the overall metabolic condition </plain></SENT>
<SENT sid="11" pm="."><plain>Short-term normalization of plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> might break the vicious cycle of impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>